A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer

@inproceedings{Rodn2016API,
  title={A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer},
  author={Jordi Rod{\'o}n and Amita Patnaik and Murray B. Stein and Anthony William Tolcher and Christine Bik-Kay Ng and Cinara Dias and Mariusz Kurman and G{\'e}rard Greig and Razelle Kurzrock and Eric H. Rubin},
  year={2016}
}
3590 Background: Insulin-like growth factor receptor (IGF-1R) is a tyrosine kinase cell surface receptor overexpressed in cancer cells which mediates the mitogenic and anti-apoptotic actions of IGF, playing a key role in malignant transformation. The safety and pharmacokinetics of 3-weekly administration of R1507, a human monoclonal antibody selective for IGF-1R, were explored in this phase I dose escalation study in patients with advanced solid tumors or lymphomas. Materials and Methods… CONTINUE READING

Topics from this paper.